AMCP Press & News

With President Trump and his administration returning to Washington, D.C., and a new Congress set to take shape, there’s naturally some uncertainty when it comes to the future of American health care policy. Looking ahead to 2025, however, there will likely be some key decisions affecting and defining how managed care pharmacy and the larger health care system operate and serve patients.

AMCP's Journal of Managed Care + Specialty Pharmacy (JMCP) December 2024 Issue

AMCP's Journal of Managed Care + Specialty Pharmacy (JMCP) December 2024 Issue

Our Associate Vice President of Congressional Affairs Adam Colborn unpacks the key issues the health policy community should be on watch for when preparing for the incoming presidential administration in a recent article for First Report Managed Care.

AMCP CEO Susan Cantrell stresses how collaboration is key in addressing challenges such as high drug prices and healthcare disparities. While there’s no silver bullet, solutions such as tailored population benefit design and value-based contracting can play an important role in making a difference for ordinary Americans looking for affordable access to prescriptions.

Because most prescription drugs selected for negotiation are highly rebated and discounted—prior to the federal government negotiations—comparisons of MFPs with list prices are somewhat misleading. Many of the ten drugs chosen already had significant rebates, in some cases as high as 68% off of the wholesale acquisition cost.

Hernandez co-authored a June study in the Journal of Managed Care & Specialty Pharmacy (JMCP) on price benchmarks for selected drugs and their therapeutic alternatives, which concluded different negotiation scenarios for the first 10 drugs. If a drug has a therapeutic alternative, that likely guided the initial price offer from the CMS.